Browsing Tag
ABP-450
2 posts
FDA engagement signals cautious progress for AEON Biopharma Inc. in complex biologics space (NYSE American: AEON)
AEON Biopharma advances ABP-450 biosimilar strategy. Discover what this means for BOTOX competition, pricing, and biotech market dynamics.
Biopharma company AEON Biopharma goes public in SPAC deal
Priveterra Acquisition Corp., a special purpose acquisition company (SPAC) chaired by Robert Palmisano, has successfully completed its business…